| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.66 [0.50, 0.86] | | < 1 | | 71% | 6 studies (6/-) | 99.9 % | low | not evaluable | high | crucial | - |
| deaths (OS) (extension) | 0.46 [0.36, 0.59] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.42 [0.33, 0.53] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.54 [0.44, 0.67] | | < 1 | | 73% | 6 studies (6/-) | 100.0 % | low | not evaluable | high | important | - |
| DOR | 0.41 [0.20, 0.83] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
| DOR (extension) | 3.45 [1.46, 8.18] | | > 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 2.92 [1.43, 5.95] | | > 1 | | 90% | 6 studies (6/-) | 99.8 % | low | not evaluable | high | non important | - |
| objective responses (ORR) (extension) | 4.50 [2.79, 7.25] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.86 [0.40, 1.86] | | < 1 | | 0% | 2 studies (2/-) | 65.2 % | low | not evaluable | high | non important | - |
| AE (grade 3-4) | 1.37 [0.48, 3.88] | | < 1 | | 84% | 2 studies (2/-) | 28.0 % | low | not evaluable | high | non important | - |
| AE leading to death (grade 5) | 1.36 [0.51, 3.61] | | < 1 | | 0% | 3 studies (3/-) | 26.6 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.00 [0.45, 2.23] | | < 1 | | 78% | 3 studies (3/-) | 50.2 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 0.61 [0.29, 1.28] | | < 1 | | 0% | 1 study (1/-) | 90.5 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 0.73 [0.49, 1.10] | | < 1 | | 0% | 1 study (1/-) | 93.1 % | NA | not evaluable | | non important | - |
| SAE (grade 3-4) | 0.74 [0.47, 1.17] | | < 1 | | 0% | 1 study (1/-) | 90.4 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 1.20 [0.86, 1.66] | | < 1 | | 0% | 2 studies (2/-) | 14.4 % | low | not evaluable | high | non important | - |
| STRAE (grade 3-4) | 0.99 [0.44, 2.27] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.76 [0.58, 1.00] | | < 1 | | 0% | 5 studies (5/-) | 97.4 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.92 [0.48, 1.76] | | < 1 | | 86% | 5 studies (5/-) | 60.4 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 1.62 [0.21, 12.60] | | < 1 | | 0% | 3 studies (3/-) | 32.4 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 1.62 [0.86, 3.05] | | < 1 | | 36% | 3 studies (3/-) | 6.8 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 2.06 [0.87, 4.87] | | < 1 | | 0% | 2 studies (2/-) | 5.1 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 0.97 [0.10, 9.36] | | < 1 | | 0% | 3 studies (3/-) | 51.0 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.12 [0.03, 0.55] | | < 1 | | 0% | 3 studies (3/-) | 99.7 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 1.28 [0.50, 3.27] | | < 1 | | 0% | 4 studies (4/-) | 30.0 % | low | not evaluable | high | non important | - |
| Asthenia TRAE (grade 3-4) | 1.41 [0.42, 4.72] | | < 1 | | 0% | 4 studies (4/-) | 28.7 % | low | not evaluable | high | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.61 [0.02, 18.27] | | < 1 | | 0% | 1 study (1/-) | 61.1 % | NA | not evaluable | | non important | - |
| Chorioretinopathy TRAE (grade 3-4) | 0.61 [0.02, 18.27] | | < 1 | | 0% | 1 study (1/-) | 61.1 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 1.66 [0.25, 11.00] | | < 1 | | 0% | 2 studies (2/-) | 30.0 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.97 [0.10, 9.36] | | < 1 | | 0% | 3 studies (3/-) | 51.0 % | some concern | not evaluable | moderate | non important | - |
| Cough TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.65 [0.10, 4.04] | | < 1 | | 0% | 4 studies (4/-) | 67.8 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.75 [0.32, 1.72] | | < 1 | | 0% | 4 studies (4/-) | 75.4 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 1.71 [0.27, 10.64] | | < 1 | | 0% | 4 studies (4/-) | 28.4 % | low | not evaluable | high | non important | - |
| Erythema TRAE (grade 3-4) | 7.41 [0.37, 148.78] | | < 1 | | 0% | 1 study (1/-) | 9.8 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.42 [0.12, 1.44] | | < 1 | | 36% | 4 studies (4/-) | 91.6 % | some concern | not evaluable | moderate | non important | - |
| Headache TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 2.26 [0.20, 25.79] | | < 1 | | 0% | 2 studies (2/-) | 25.8 % | some concern | not evaluable | moderate | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.99 [0.34, 11.63] | | < 1 | | 0% | 4 studies (4/-) | 22.4 % | low | not evaluable | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.43 [0.11, 18.64] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.97 [0.10, 9.36] | | < 1 | | 0% | 3 studies (3/-) | 51.0 % | some concern | not evaluable | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 1.00 [0.06, 16.02] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.00 [0.18, 22.23] | | < 1 | | 0% | 1 study (1/-) | 28.8 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 0.99 [0.64, 1.52] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.08 [0.02, 0.43] | | < 1 | | 0% | 3 studies (3/-) | 99.8 % | some concern | not evaluable | moderate | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.39 [0.82, 2.38] | | < 1 | | 0% | 4 studies (4/-) | 11.2 % | low | not evaluable | high | non important | - |
| Myalgia TRAE (grade 3-4) | 1.51 [0.36, 6.24] | | < 1 | | 0% | 4 studies (4/-) | 28.6 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 0.21 [0.06, 0.77] | | < 1 | | 0% | 4 studies (4/-) | 99.1 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.07 [0.01, 0.36] | | < 1 | | 0% | 3 studies (3/-) | 99.9 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 1.42 [0.11, 18.63] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.16 [0.01, 3.29] | | < 1 | | 0% | 1 study (1/-) | 87.9 % | NA | not evaluable | | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.97 [0.10, 9.36] | | < 1 | | 0% | 3 studies (3/-) | 51.0 % | some concern | not evaluable | moderate | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.24 [0.03, 2.13] | | < 1 | | 0% | 2 studies (2/-) | 89.9 % | some concern | not evaluable | moderate | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 1.22 [0.02, 61.84] | | < 1 | | 0% | 1 study (1/-) | 46.1 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 4.00 [0.65, 24.72] | | < 1 | | 0% | 3 studies (3/-) | 6.9 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 1.71 [0.34, 8.51] | | < 1 | | 0% | 4 studies (4/-) | 25.6 % | low | not evaluable | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 1.04 [0.24, 4.45] | | < 1 | | 0% | 2 studies (2/-) | 48.0 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 1.00 [0.55, 1.80] | | < 1 | | 0% | 4 studies (4/-) | 50.6 % | low | not evaluable | high | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.13 [0.03, 0.56] | | < 1 | | 0% | 3 studies (3/-) | 99.7 % | some concern | not evaluable | moderate | non important | - |
| Uveitis TRAE (grade 3-4) | 1.42 [0.11, 18.63] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.97 [0.10, 9.36] | | < 1 | | 0% | 3 studies (3/-) | 51.0 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 0.39 [0.14, 1.10] | | < 1 | | 0% | 4 studies (4/-) | 96.2 % | low | not evaluable | high | non important | - |
AE (grade 3-4) endpoints 00 |
| Hypothyroidism AE (grade 3-4) | 1.22 [0.02, 61.84] | | < 1 | | 0% | 1 study (1/-) | 46.1 % | NA | not evaluable | | non important | - |
